Premium
Pharmacokinetics of controlled‐release carbimazole tablets support once daily dosing in cats
Author(s) -
FRÉNAIS R.,
BURGAUD S.,
HORSPOOL L. J. I.
Publication year - 2008
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.2008.00949.x
Subject(s) - carbimazole , pharmacokinetics , bioavailability , cats , oral administration , pharmacology , medicine , bioequivalence , dosing , dosage form , graves' disease , disease
Carbimazole, a prodrug of methimazole, is used in the treatment of hyperthyroidism in cats. The pharmacokinetics of methimazole was investigated in healthy cats following oral administration of 15 mg of carbimazole as a controlled‐release tablet (Vidalta ® , Intervet). The controlled‐release tablet did not produce a pronounced concentration peak and methimazole was present in the circulation for a sustained period, compared with a conventional tablet formulation. The time to reach peak concentrations after carbimazole administration was quite long (t max 6 h). The absolute bioavailability of carbimazole was around 88 ± 11%. Repeated oral administration daily for 13 consecutive days did not lead to accumulation of methimazole in plasma. The extent of absorption of carbimazole was about 40% higher when administered to cats that had been fed compared to fasted cats. The relative oral bioavailability of methimazole following administration of the controlled‐release tablets was similar to that of a conventional release formulation (83 ± 21%). The pharmacokinetics of this controlled‐release formulation of carbimazole supports its use as a once daily treatment (both as a starting dose and for maintenance therapy) for cats with hyperthyroidism.